UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000044803
Receipt No. R000051168
Scientific Title Study on the effects of research food intake on fatigue, sleep, and concentration.
Date of disclosure of the study information 2021/07/11
Last modified on 2022/01/06 (Ver. 3)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Study on the effects of research food intake on fatigue, sleep, and concentration.
Acronym Study on the effects of research food intake on fatigue, sleep, and concentration.
Scientific Title Study on the effects of research food intake on fatigue, sleep, and concentration.
Scientific Title:Acronym Study on the effects of research food intake on fatigue, sleep, and concentration.
Region
Japan

Condition
Condition Healthy adult (worker)
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To examine the effects of QOL Bacillus subtilis subsp. natto-containing food on fatigue, sleep, and concentration after 8 weeks of continuous intake, using placebo as a control.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes (1) Athens Insomnia Scale
(2) The Japanese version of the Pittsburgh Sleep Quality Index
(3) OSA sleep inventory MA version
Evaluate before ingestion and 4 to 8 weeks after ingestion.
Key secondary outcomes (1) Salivary s-IgA secretion rate
(2) Stress markers in the blood (DHEA-S, Cortisol)
(3) POMS2 shortened version for adults
(4) Fatigue VAS
(5) Fatigue accumulation self-diagnosis checklist
(6) Uchida-Kraepelin test
(7) Purdue Pegboard Test
Evaluate before ingestion and 4 to 8 weeks after ingestion.

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 2 grains of the test product daily oral intake for 8 weeks.
Interventions/Control_2 2 grains of the placebo daily oral intake for 8 weeks.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
64 years-old >=
Gender Male and Female
Key inclusion criteria (1) Healthy worker between the ages of 20 and 64.
(2) Subjects with a total score of 6 or more on the Pittsburgh questionnaire at the time of pre-examination.
Key exclusion criteria (1) Subjects who routinely use food containing of abundant Bacillus natto, health foods, quasi-drugs, or drugs.
(2) Subjects who act for the purpose of improving sleep, stress, fatigue (including hospital visits and treatment), and use medicines and health foods.
(3) Night and day shift worker or manual laborer.
(4) Subjects who have a disease that is being treated or who have a disease that is deemed to require treatment.
(5) Subjects who are under treatment or have a history of serious diseases (e.g., diabetes, liver disease, kidney disease, or heart disease).
(6) Subjects who are a history of mental illness (e.g., depression).
(7) Subjects having possibilities for emerging allergy related to the study.
(8) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire and other questionnaires.
(9) Subjects who cannot carry out the procedures of various tests to be carried out during this study.
(10) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination before intake.
(11) Subjects who have participated in other clinical study within the last one month prior to the current study or are planned to participate in other clinical study after informed consent for the current study.
(12) Subjects who are planned to become pregnant or are pregnant or lactating.
(13) Subjects who are judged as unsuitable for the study by the investigator for other reason.
Target sample size 60

Research contact person
Name of lead principal investigator
1st name Naoki
Middle name
Last name Nakamura
Organization IKEDA FOOD RESEARCH CO.,LTD
Division name Food Science and Technology Institute
Zip code 721-0956
Address 95-7, Minooki-cho, Fukuyama-city, Hiroshima, Japan
TEL 084-957-3411
Email n.nakamura@ikedatohka.co.jp

Public contact
Name of contact person
1st name Shingo
Middle name
Last name Yamamichi
Organization EP Mediate Co., Ltd.
Division name Development Business Headquarters, TTC Center, Trial Planning Department
Zip code 162-0822
Address Tsuruya Bldg., 2-23 Shimomiyabicho, Shinjuku-ku, Tokyo
TEL 03-5657-4983
Homepage URL
Email yamamichi.shingo578@eps.co.jp

Sponsor
Institute EP Mediate Co., Ltd.
Institute
Department

Funding Source
Organization IKEDA FOOD RESEARCH CO.,LTD
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Medical Station Clinic Research Ethics Committee
Address 3-12-8, Takaban, Meguroku, Tokyo
Tel 03-6452-2712
Email saito.teruo876@eps.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2021 Year 07 Month 11 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2021 Year 06 Month 24 Day
Date of IRB
2021 Year 06 Month 24 Day
Anticipated trial start date
2021 Year 07 Month 12 Day
Last follow-up date
2021 Year 12 Month 11 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2021 Year 07 Month 08 Day
Last modified on
2022 Year 01 Month 06 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051168